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incidence and prevention
The incidence of malignant melanoma varies from 3–5/
100 000/year in Mediterranean countries to 12–20 in Nordic
countries and is still rising [1]. Increased ultraviolet (UV) light
exposure of a genetically predisposed population seems to be at
least in part responsible for an ongoing increase in incidence
and mortality over recent decades [2].
UV light was identiﬁed as a major carcinogen involved in
melanomagenesis. Prevention of UV exposure including the
regular use of sunscreen has been shown to diminish the
incidence of primary cutaneous melanomas in an Australian
population [3].
diagnosis
Suspicious lesions are characterized by Asymmetry, Border
irregularities, Color heterogeneity, Dynamics (Dynamics or
evolution in colors, elevation or size) (‘ABCD rule’) [4]. Today,
many primary melanomas have a diameter of <5 mm [5].
The ugly duckling ‘concept’ [6] helps us to identify
melanomas, because nevi in the same individual tend to
resemble one another and melanomas often do not ﬁt in the
individual nevus pattern.
Dermoscopy by an experienced physician enhances the
diagnostic accuracy (II, B).
Diagnosis should be based on a full thickness excisional
biopsy with a small side margin. Processing by an experienced
pathology institute is mandatory.
The histology report should follow the American Joint
Committee on Cancer (AJCC) classiﬁcation [7] and includes
information on the maximum thickness in millimeters
(Breslow), information on the mitotic rate, presence of
ulceration, presence and extent of regression and clearance of
the surgical margins (II,A). In addition, information on the
anatomical site (including extra cutaneous sites, such as
mucosa and conjunctiva), and the degree of sun damage is
necessary. It describes the melanoma type (superﬁcial
spreading melanoma, lentigo maligna melanoma,
acrolentiginous melanoma, nodular melanoma, others). In rare
situations, melanomas may derive from dermal melanocytes
(melanoma arising from giant congenital nevus, malignant
blue nevus) [8].
Superﬁcial spreading and nodular melanomas present a
much higher frequency of BRAF and NRAS mutations than
other melanoma types. Acrolentiginous melanoma and
mucosal melanomas of the genital region have a certain
probability to present c-Kit mutations [9]. Mutation analysis
for BRAF and optionally NRAS and c-Kit are necessary in the
case of metastatic disease. Mutational testing of primary
tumors without metastases is not recommended. Mutation
analysis must be carried out in accredited (certiﬁed) institutes
including careful quality controls.
staging examinations
Physical examination with special attention to other suspicious
pigmented lesions, tumor satellites, in-transit metastases,
regional lymph node and systemic metastases is mandatory.
In low-risk melanomas (pT1a), no other investigations are
necessary. In higher tumor stages, imaging is recommended in
order to allow proper staging (III, C).
The reﬁned version of the AJCC staging and classiﬁcation
system which includes a sentinel node staging is the only
internationally accepted classiﬁcation system [7, 10] (Table 1).
treatment of localized disease
Wide excision of primary tumors with safety margins of
0.5 cm for in situ melanomas, of 1 cm for tumors with a
Breslow thickness of up to 2 mm and 2 cm for thicker
tumors is recommended [11] [II, B]. Modiﬁcations may be
needed for preservation of function in acral and facial
melanomas.
†Approved by the ESMO Guidelines Working Group: August 2008, last update June
2012. This publication supersedes the previously published version—Ann Oncol 2010;
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Routine elective lymphadenectomy or irradiation to the
regional lymph nodes is not recommended [II, B].
Sentinel lymph node biopsy in melanoma with a tumor
thickness of >1 mm and/or ulceration is necessary for precise
staging (II, B). It should be followed by a complete
lymphadenectomy of regional lymph nodes, if the sentinel
node was found positive for metastases (III, C). However, this
procedure has no proven effect on overall survival (OS) [12].
Sentinel lymph node biopsy should be carried out only by
skilled teams in experienced centers.
Many well designed clinical trials have investigated the
impact of adjuvant therapy in patients with high-risk primary
melanoma (stage IIB/C) or completely resected lymph node
metastases (stage III) [6]. A number of prospective randomized
trials have investigated adjuvant treatment with low,
intermediate and high doses of IFN-α [13, 14].
The ﬁrst trial that showed a positive effect in OS was ECOG
1684 [15] which randomized 287 patients with node-positive
melanoma to high-dose interferon-α (IFN-α) for 1 year versus
observation. Five-year disease-free survival (DFS) was 37%
versus 26% and OS was 46% versus 37% [15]. On this basis,
high-dose adjuvant IFN-α won US Food and Drug
Administration (FDA) approval. A meta-analysis of 14
randomized, controlled trials investigating adjuvant IFN
therapy involving 8122 patients showed statistically signiﬁcant
improvement in both DFS and OS [16]. Since pegylated IFN-α
(PegIFN-α) is suitable for long-term therapy, the European
Organization for Research and Treatment of Cancer has
initiated a large prospective randomized trial to investigate the
protective effect of PegIFNα-2b in the adjuvant setting [17].
One thousand two hundred and ﬁfty six patients with resected
stage III melanoma were randomly assigned to receive
observation or PegIFN-α therapy [17]. Randomization was
stratiﬁed for microscopic (N1) versus macroscopic (N2) nodal
involvement, number of positive nodes, ulceration and tumor
thickness. Relapse-free survival (RFS) (primary end-point),
distant-metastases-free survival (DMFS) and OS were analyzed
for the intent-to-treat population. The IFN group received an
induction IFN dose of 6 μg/kg weekly for the ﬁrst 8 weeks and
then the dose was reduced to 3 μg/kg per week for 5 years [17].
At 3.8 years of median follow-up, RFS was substantially
improved by 18% in the PegIFNα-2b arm compared with
observation; the 4-year RFS rate was 45.6% versus 38.9%. OS
was unchanged in the two groups. In stage III-N1a
(micrometastases detected in the sentinel node) both RFS
(HR = 0.72, 57.7% versus 45.4%, P = 0.01) and DMFS
(HR = 0.73, 60.5% versus 52.6%, P = 0.01) were prolonged in
the PegIFNα-2b arm, whereas in stage III-N1b (macroscopic
metastases) there was no beneﬁt [17]. This trial showed that a
prolonged adjuvant treatment with IFN-α improved the RFS
period and DMFS in a subgroup of patients with low tumor
burden [17]. An update of this trial with median follow-up of
7.6 years has shown that IFN therapy had a substantial impact
on RFS, DMFS and OS (HR 0.59 = 0.006) in a subpopulation
of patients with micrometastases and primary ulcerated
melanomas. Therefore, in this patient population pegylated
IFN can be recommended, if the individual patient tolerates it
well (II, B). Adjuvant treatment in patients with resected
macroscopic node involvement is preferentially applied in the
context of randomized clinical trials in specialized centers.
However, high-dose IFN a2b is an approved indication for this
therapeutic situation. A recent meta-analysis on adjuvant
therapy of melanoma with IFN did not demonstrate an
improved efﬁcacy of high-dose IFN compared with low- or
intermediate-dose IFN [16].
Adjuvant chemotherapy, mistletoe extracts, viscum album
and hormone therapies are not beneﬁcial at all [18]. Adjuvant
therapy with other cytokines including interleukin-2 (IL-2),
tumor vaccination, immunochemotherapy and BRAF
inhibitors are experimental and not to be used outside
controlled clinical trials. The application of vemurafenib is
associated with cutaneous neoplasms such as
keratoakanthomas, squamous cell carcinomas and melanomas
[19–21]. Therefore, it is not recommended in patients without
measurable tumor load.
Table 1. AJCC Staging system of melanoma [7].
Classiﬁcation Thickness (mm) Ulceration status/mitoses
T
Tis NA NA
T1 ≤1.00 (a) Without ulceration and
mitosis < 1/mm²
(b) With ulceration or
mitoses ≥1/mm²
T2 ≤2.00 (a) Without ulceration
(b) With ulceration
T3 2.01–4.00 (a) Without ulceration
(b) With ulceration
T4 >4.00 (a) Without ulceration
(b) With ulceration
N No. of Metastatic nodes Nodal Metastatic Burden
N0 0 NA
N1 1 (a) Micrometastasisa
(b) Macrometastasisb
N2 2–3 (a) Micrometastasisa
(b) Macrometastasisb
(c) In transit metastases/
satellites without
metastatic nodes
N3 4+ metastatic nodes, or
matted nodes, or in transit
metastases/satellites with
metastatic nodes
M Site Serum LDH
M0 No distant metastases NA
M1a Distant skin, subcutaneous or
nodal metastases
Normal
Lung metastases
M1b All other visceral metastases Normal
Any distant metastases Normal
M1c Elevated
aMicrometastases are diagnosed after sentinel lymph node biopsy.
bMacrometastases are deﬁned as clinically detectable nodal metastases
conﬁrmed pathologically.
NA, not applicable; LDH, lactate dehydrogenase.
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Radiotherapy for local tumor control should be considered
in case of inadequate resection margins of lentigo maligna
melanoma [22] or R1 resections of melanoma metastases when
surgery is not adequate (III, B).
treatment of locoregional disease
In the case of isolated locoregional lymph node metastases,
surgical removal, including the surrounding lymph node
region, is indicated (III, C); removal of the tumor-bearing
lymph node alone is insufﬁcient. In high-risk situations such as
multiple bulky lymph node metastases, postoperative
radiotherapy can improve local tumor control [23].
Surgical removal is also recommended in the case of a single
metastasis in parenchymal organs, including the central
nervous system. However, before undertaking additional
aggressive local surgical treatments, a detailed staging
investigation, including imaging techniques such as Positron
Emission Tomography (PET) and computed tomography
(CT), is necessary to exclude the presence of further metastases
[4] (III, B).
Non-resectable in-transit metastases or inoperable primary
tumors of the limbs without additional metastases may be
treated with isolated limb perfusion using, e.g. melphalan and/
or tumor necrosis factor-α [III, C]. Such treatment requires
major surgery and should be restricted to centers of excellence.
Radiation therapy may be used alternatively [V, C], although
there are no data showing a positive effect on any outcome
measure [23, 24] (Table 2).
treatment of systemic metastatic
disease (stage IV)
Recently new therapeutic strategies such as immunotherapy
using Ipilimumab or anti-PD1 antibodies, selective BRAF
inhibitors like vemurafenib and dabrafenib, c-Kit inhibitors
and MAPK/ERK kinase (MEK) inhibitors [25, 26] have
demonstrated impressive antitumor activity in clinical trials
[27–30]. Ipilimumab and vemurafenib, dabrafenib and
trametinib have substantially improved response rates and/or
survival of the patient population included in prospective
randomized trials [25, 27, 29, 30].
Tumor tissues preferentially of metastatic lesions should be
screened for mutations (BRAF, NRAS, c-Kit, GNA11, GNAQ)
which help to direct patients to the appropriate clinical trials
and in the long term to validate their prognostic relevance.
Ipilimumab and in the presence of BRAF V600 mutation,
vemurafenib, are optimal choices for ﬁrst-line therapy of patients
with metastatic melanoma (II, B). Phase III randomized,
controlled trials resulted in the approval of vemurafenib by the
United States Food & Drug Administration (FDA) and
European Medicines Agency (EMA) and of ipilimumab for ﬁrst-
and second-line therapy (FDA) or as second-line therapy (EMA)
of patients with advanced irresectable melanoma.
If the patient suffers from symptomatic, bulky metastases
from a BRAF V600 mutated melanoma, a selective inhibitor
such as vemurafenib is preferred, because it has a high chance
for a rapid response including improvement of the quality of
life. There are no mature data to guide decision-making
regarding the sequencing of ipilimumab and vemurafenib in
Table 2. Treatment modalities for melanoma metastases.
Number and localization of the metastases Treatment modalities
(i) First choice
(ii) Second choice
(iii) Third choice
Grade of
recommendation
In-transit metastases (few) (pTXN2cM0) (i) Surgical removal C
(ii) Radiotherapy C
In-transit metastases (multiple, >5) (pTXN2cM0)(i) Perfusion of the extremitya C
(ii) Radiotherapy C
(iii) Systemic therapya C
Locoregional lymph nodes (pTxN1a,2a) (i) Resection and trial participation B
(ii) Additional IFN-α treatmenta B
Locoregional lymph nodes (pTxN2b,2c,3) (i) Radical lymphadenectomy, in case of incomplete resection: irradiation C
(ii) Consider trial participation C
Solitary central nervous system metastases
(pTxNxM3)
(i) Neurosurgical removal C
(ii) Stereotactic irradiationa (according to localization this could also be the
ﬁrst choice)
C
(iii) Consider clinical trial participation
Solitary lung metastases (pTxNxM1) (i) Surgical removal C
(ii) Consider clinical trial participation
(iii) Systemic therapya C
Multiple metastases (pTxNxM1a-1c) (i) Consider clinical trial participation
(ii) Systemic therapya B
Painful bone metastases (pTxNxM1a-1c) (i) Consider clinical trial participation
(ii) Radiotherapy C
aThese therapies should be preferentially carried out at specialized centers.
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patients with BRAF-mutant metastatic melanoma; however
emerging data suggest that BRAF inhibition is effective even
following immunotherapy. Currently, ipilimumab is only
approved by EMA as second-line therapy for patients with
advanced disease. Selective BRAF inhibitors can be safely used
in patients with brain metastases and show promising efﬁcacy
in this compartment. Patients treated with vemurafenib should
be carefully followed with special attention to skin [19, 21] and
other secondary neoplasms.
In patients with BRAF wild-type melanomas ipilimumab, an
agent blocking cytotoxic T-lymphocyte-associated protein 4
(CTLA4) and thus activating T-lymphocytes to mount an immune
response against tumor cells, is a recommended second-line to
ﬁrst-(FDA) or second-line (FDA and EMA) therapeutic option. In
the context of new developments and medical progress, there are
continuously new experimental treatment options for patients with
advanced metastatic melanoma. Therefore, these patients should
be referred to tertiary centers providing a comprehensive clinical
trial program. There are early signals that patients with metastatic
melanomas carrying NRAS mutation will proﬁt from MEK kinase
inhibitor therapy [26].
If clinical trials or the approved new targeted compounds are
not available, cytotoxic drugs such as dacarbazine (DTIC),
temozolomide, taxanes, fotemustine, platin derivatives or
others, cytokines ( IFN, IL-2) or combinations may be applied.
Dacarbazine is still considered a reference drug in this
situation. In aggressive metastastic disease, multi-agent
polychemotherapy containing paclitaxel and carboplatin or
cisplatin, vindesine and dacarbazine produce partial response
rates and stabilizations in a meaningful number of patients.
Despite a better initial control rate, no survival beneﬁt has
been shown with polychemotherapy when compared with
monochemotherapy, and therefore, polychemotherapies are
not considered an established ﬁrst-line therapy. Despite a
minor increase in progression-free survival, bevacizumab
therapy is rarely used in metastatic melanoma [31, 32].
There are no randomized clinical trials for IL-2
monotherapy. Some centers still use IL-2 as ﬁrst-line therapy
when disease burden is low [33, 34]. Several randomized trials
did not show any survival beneﬁt for the very intensive
biochemotherapy including IL-2.
Surgery of visceral metastases may be appropriate for selected
cases with good performance status and isolated tumor manifes-
tations. In principal, the goal is R0-resections in these patients.
Palliative radiotherapy should be considered, especially for
symptomatic brain or localized and painful bone metastases.
Stereotactic irradiation is preferred in case of few brain
metastases [23].
In general, stage IV melanoma patients need to be treated
and discussed in an interdisciplinary tumor board at centers
with broad experience in this disease.
patient information and follow-up
Melanoma patients should be instructed on avoidance of
sunburns, extended unprotected solar or artiﬁcial UV exposure
and on lifelong regular self-examinations of the skin and
peripheral lymph nodes. Patients must be aware that family
members have an increased melanoma risk (III, B). There is no
necessity for genetic testing.
During melanoma follow-up, patients are clinically
monitored in order to detect a relapse and to recognize
additional skin tumors, especially secondary melanomas, as
early as possible [4] (III, B). However, it is unproven if this
policy leads to improved survival rates. Eight percent of all
melanoma patients develop a secondary melanoma within 2
years of their initial diagnosis [35]. Melanoma patients also
have increased risks of other skin tumors. In patients with
lentigo maligna melanomas, 35% of the patients developed
another cutaneous malignancy within 5 years [22].
There is currently no consensus on the frequency of follow-up
and the use of imaging techniques. In recent series, most relapses
have been detected by the patients themselves, questioning the
Table 3. Summary of recommendations
Diagnosis should be based on a full thickness excisional biopsy with a
small side margin (II, A)
The histology report should include at least information on the type of
melanoma, actinic damage, maximum thickness in millimeters
(Breslow), information on the mitotic rate in case of pT1, presence of
ulceration, presence and extent of regression and clearance of the
surgical margins (II,A)
Physical examination with special attention to other suspicious pigmented
lesions, tumor satellites, in-transit metastases, regional lymph node and
systemic metastases is mandatory. In low-risk melanomas (pT1a), no
other investigations are necessary. In higher tumor stages, imaging is
recommended in order to allow proper staging (III, C)
Wide excision of primary tumors with safety margins of 0.5 cm for in situ
melanomas, of 1 cm for tumors with a Breslow thickness of up to 2 mm
and 2 cm for thicker tumors is recommended (II, B)
Sentinel lymph node biopsy in melanoma with a tumor thickness of >1
mm and/or ulceration is necessary for precise staging (II, B)
Patients with resected stage III melanomas should be evaluated for
adjuvant therapy with either high-dose IFN-α2b for 1 year or with
pegylated weekly PegIFN-α for up to 5 years (II, B). Subgroup analyses
suggest that patients with microscopic regional nodal involvement and/
or ulcerated primaries are the ones most likely to beneﬁt from adjuvant
IFN-α. Participation in clinical trials should be encouraged
Surgical removal of locoregional recurrence or single distant metastasis
should be considered in ﬁt patients as a therapeutic option offering
potential for long-term disease control (III, C)
Patients with metastatic melanoma should have a metastasis (preferably) or
the primary screened for the presence of BRAF V600 mutation.
Treatment options for the ﬁrst- and second-line setting include
ipilimumab, an anti-CTLA4 antibody, for all patients and vemurafenib, a
BRAF inhibitor, for patients with BRAF-mutant melanoma (II, B).
Ipilimumab is approved only as 2nd line therapy by EMA
If clinical trials or the approved new targeted compounds are not available,
cytotoxic drugs such as DTIC, temozolomide may be applied, with
modest activity shown (II, C)
Melanoma patients should be instructed on avoidance of sunburns,
extended unprotected solar or artiﬁcial UV exposure and on lifelong
regular self-examinations of the skin and peripheral lymph nodes (III, B)
There is no consensus on optimal schedule, frequency of follow-up visits
neither on the utility of imaging and blood tests for patients with
resected melanoma
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usefulness and cost-effectiveness of follow-up visits every 3
months during the ﬁrst 3 years and every 6–12 months thereafter.
The above recommendations were solely based on the relapse-
risk proﬁle over time [4]. Intervals between controls tailored
according to individual risk may reduce false-positive ﬁndings
and sufﬁce for psychological support of the patients [36].
Since patients with a thin primary melanoma have only a
small risk of relapse, routine imaging techniques are
deﬁnitively not recommended for this patient population. In
high-risk patients,, e.g. those with thick primary tumors or
following treatment of metastases ultrasound of lymph nodes,
computed tomography (CT) or whole body positron emission
tomography scans (PET)/PET–CT scans may lead to an earlier
diagnosis of regional or systemic relapses [37]. However, an
impact of radiological exams upon survival has not been
demonstrated so far [38]. Rising serum S-100 has a higher
speciﬁcity for disease progression than lactate dehydrogenase
(LDH) and therefore is the most accurate blood test in the
follow-up of melanoma patients [39], if any blood test is
recommended at all (IV, D).
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